The UICC (Union Internationale Contre le Cancer, International Union Against Cancer) developed criteria for evaluating the response of metastatic bone lesions to cancer therapy.
Findings
Response Classification
disappearance of all known bone disease; lytic lesions should show evidence of becoming calcified
complete response
(>= 50% reduction in bone lesions) AND (no bone lesions have progressed) AND (no new bone lesions) AND (objective improvement)
partial response
(measurable lesions are unchanged, increase in by <= 25% or decrease in size by < 50%) AND no new lesions
no change (stable disease)
(progression of some bone lesions and/or appearance of new bone lesions) AND (some bone lesions regress)
progressive disease, mixed
(progression of some bone lesions) AND/OR appearance of new bone lesions) AND (no bone lesions regress)
progressive disease, failure
where:
• If unmeasurable lesions form the bulk of metastatic bone involvement and if these do not regress with therapy, then the response is considered no change even if there has been regression of measurable lesions.
• In complete response all lytic bone lesions must be calcified on X-rays.
• In partial response not all bone lesions have to regress.
• "No lesions regress" was listed as an indicator of progressive disease, but this overlaps with no change (stable disease).
• Progressive disease encompasses "failure" (lesions increase in size and/or number) and "mixed" response (some lesions regress and some increase).
To read more or access our algorithms and calculators, please log in or register.
